14. Chronic inflammatory demyelinating polyneuropathy Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 302 / Drugs : 231 - (DrugBank : 32) / Drug target genes : 16 - Drug target pathways : 67
Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)
0.9% sodium chloride
University of Toronto
2015 Phase 4 NCT02372149 Canada
10% liquid formulation OF human immunoglobulin
CSL Behring
2010 Phase 3 NCT01184846 Belgium;Finland;France;Germany;Poland
ACT-HIB
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Alemtuzumab infusion
Johns Hopkins University
2012 Phase 4 NCT01757574 United States
ANTI-C5 antibody
Greater Glasgow and Clyde NHS Board and The University Of Glasgow
2009 - EUCTR2008-005748-18-GB United Kingdom
ANTI-thymocyte globulin
Fred Hutchinson Cancer Center
2008 Phase 2 NCT00716066 United States
ARGX-113
ARGENX BV
2020 Phase 2 EUCTR2019-003107-35-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
argenx BVBA
2021 Phase 2 EUCTR2019-003107-35-RO Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003107-35-CZ Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003107-35-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003076-39-RO Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003076-39-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-DE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-BE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-PL Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-LV Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-DE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-BE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
ARGX-117
argenx
2023 Phase 2 NCT05405361 Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 NCT05225675 Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
ARGX-117 IV
ARGENX BV
2022 Phase 2 EUCTR2021-004998-32-IT Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
argenx BV
2023 Phase 2 EUCTR2021-004998-32-DE Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2023 Phase 2 EUCTR2021-004998-32-AT Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-004998-32-NL Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-004998-32-FR Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-004998-32-ES Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-004998-32-BE Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-003302-50-PL Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-003302-50-NL Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-003302-50-FR Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-003302-50-ES Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-003302-50-DE Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-003302-50-BE Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-003302-50-AT Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Autologous hematopoietic stem cell transplantation
Fred Hutchinson Cancer Center
2008 Phase 2 NCT00716066 United States
BAFF-R cart
Tianjin Medical University General Hospital
2025 Phase 1/Phase 2 NCT07022197 China
Batoclimab
Immunovant Sciences GmbH
2025 Phase 2 NCT07188844 Argentina;Belgium;Brazil;Germany;Greece;Italy;Poland;Romania;Serbia;Slovakia;United States
Immunovant Sciences, GmbH
2023 Phase 2 EUCTR2022-002718-17-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-SE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-RO Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-NO Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-FI Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-DK Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-DE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-BG Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-BE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
Batoclimab 340 MG SC weekly
Immunovant Sciences GmbH
2022 Phase 2 NCT05581199 Argentina;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Italy;Korea, Republic of;Norway;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
Batoclimab 680 milligrams (MG) subcutaneous (SC) weekly
Immunovant Sciences GmbH
2022 Phase 2 NCT05581199 Argentina;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Italy;Korea, Republic of;Norway;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
BIVV020
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 2 EUCTR2020-004006-54-IT Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain;United Kingdom;United States
Sanofi-Aventis Recherche & Développement
2021 Phase 2 EUCTR2020-004006-54-PL Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain
2021 Phase 2 EUCTR2020-004006-54-NL Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain
2021 Phase 2 EUCTR2020-004006-54-FR France;Germany;Italy;Netherlands;Poland
2021 Phase 2 EUCTR2020-004006-54-DE Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain
Blood sample
University of Aarhus
2015 - NCT02271724 Denmark
Blood sampling
Centre Hospitalier Universitaire de Nimes
2021 Early Phase 1 NCT04742374 France
Carmustine
Fred Hutchinson Cancer Center
2008 Phase 2 NCT00716066 United States
CD19/BCMA-targeted CAR-T cells
Tongji Hospital
2025 Early Phase 1 NCT07337785 China
Clairyg 50 MG/ML
LFB BIOTECHNOLOGIES
2013 Phase 3 EUCTR2012-001996-34-FR France
Clairyg 50MG/ML
LFB BIOTECHNOLOGIES
2013 Phase 3 EUCTR2012-001996-34-FR France
Claseprubart
Dianthus Therapeutics
2025 Phase 3 NCT06858579 Argentina;Australia;Belgium;Brazil;Bulgaria;China;Colombia;Croatia;Denmark;France;Georgia;Germany;Israel;Italy;Latvia;Malaysia;Netherlands;North Macedonia;Philippines;Poland;Romania;Serbia;South Korea;Spain;Thailand;United Kingdom;United States
2024 Phase 2 NCT06537999 Denmark;France;Italy;Netherlands;North Macedonia;Poland;Serbia;Spain;United Kingdom;United States
Clorfenamina maleato
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2017-005034-36-IT Italy
Conventional therapy
Sichuan Academy of Medical Sciences
2025 - NCT07597733 China
CT103A cells
Tongji Hospital
2020 Early Phase 1 NCT04561557 China
Cyclophosphamide
Kite, A Gilead Company
2026 Phase 1 NCT07304154 Australia;United States
Stony Brook University
2003 Phase 2 NCT01236456 United States
Tongji Hospital
2026 Phase 1 NCT07526493 China
Cyclophosphamide and fludarabine
Tongji Hospital
2020 Early Phase 1 NCT04561557 China
Cyclosporine
CIDP Study Group
2006 - JPRN-UMIN000000674 Japan
Cytarabine
Fred Hutchinson Cancer Center
2008 Phase 2 NCT00716066 United States
D-biotin
MEDDAY PHARMACEUTICALS
2016 Phase 2 EUCTR2015-001150-15-FR France
Dexamethasone
AMC Medical research BV
2006 - EUCTR2004-002783-24-GB United Kingdom
Eculizumab
Greater Glasgow and Clyde NHS Board and The University Of Glasgow
2009 - EUCTR2008-005748-18-GB United Kingdom
Efgartigimod
The First Affiliated Hospital of Chongqing Medical University.
2025 - ChiCTR2600119272 China
argenx
2023 - NCT06299748 Germany;Italy;Spain;United States
Efgartigimod alfa
ARGENX BV
2020 Phase 2 EUCTR2019-003107-35-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
argenx BVBA
2021 Phase 2 EUCTR2019-003107-35-RO Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003107-35-CZ Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003107-35-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003076-39-RO Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003076-39-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-DE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-BE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-PL Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-LV Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-DE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-BE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Efgartigimod PH20 SC
ARGENX BV
2020 Phase 2 EUCTR2019-003107-35-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
Tsuruyama Eri
2021 Phase 2 JPRN-jRCT2051210001 Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russia;Serbia;Spain;UK;US;Ukraine
2021 Phase 2 JPRN-jRCT2051200151 Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russia;Serbia;Spain;UK;US;Ukraine
argenx
2025 - NCT07264426 Germany;United States
2024 Phase 4 NCT06637072 United States
2022 - NCT04777734 Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United States
2020 Phase 2 NCT04280718 Austria;Belgium;Bulgaria;China;Czechia;Denmark;France;Georgia;Germany;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russia;Serbia;Spain;Taiwan;Turkey (Türkiye);Ukraine;United Kingdom;United States
argenx BVBA
2021 Phase 2 EUCTR2019-003107-35-RO Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003107-35-CZ Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003107-35-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003076-39-RO Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003076-39-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-DE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-BE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-PL Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-LV Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-DE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-BE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Efgartigimod PH20 SC IN stage B
argenx
2020 Phase 2 NCT04281472 Austria;Belgium;Bulgaria;China;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Empasiprubart
argenx
2025 Phase 3 NCT06920004 Argentina;Austria;Czechia;Estonia;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Slovenia;South Korea;Spain;Sweden;Switzerland;Turkey (Türkiye);United Kingdom;United States
2024 Phase 3 NCT06742190 Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Latvia;Lithuania;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;Slovenia;Spain;Switzerland;United Kingdom;United States
Empasiprubart IV
Kamino Eriko
2026 Phase 3 JPRN-jRCT2021250030 Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Korea;Spain
2025 Phase 3 JPRN-jRCT2051250110 Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Korea;Spain;Sweden;Switzerland;Tunisia;Turkey;USA;United Kingdom
Narita Takanori
2025 Phase 3 JPRN-jRCT2061250020 Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Italy;Japan;Korea;Latvia;Lithuania;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;Slovenia;Spain;Sweden;Switzerland;United Kingdom;United States
argenx
2026 Phase 2/Phase 3 NCT07638566 -
2026 Phase 1 NCT07610564 -
2025 Phase 3 NCT07091630 Argentina;Austria;Bulgaria;China;Czechia;Denmark;Estonia;France;Georgia;Greece;Italy;Japan;Moldova;Poland;Romania;Singapore;Slovakia;South Korea;United Kingdom;United States
Etoposide
Fred Hutchinson Cancer Center
2008 Phase 2 NCT00716066 United States
Fampridine
Department of Neurology, Odense University Hospital
2020 Phase 2 EUCTR2020-002438-34-DK Denmark
Fampyra
Department of Neurology, Odense University Hospital
2020 Phase 2 EUCTR2020-002438-34-DK Denmark
Fibrinogen concentrate
University Medical Centre Ljubljana
2018 - NCT03801135 Slovenia
Fingolimod
Novartis Pharmaceuticals
2012 Phase 3 NCT01625182 Australia;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
Tanabe Pharma Corporation, Novartis Pharma K.K.
2012 Phase 3 JPRN-jRCT2080221916 -
Fingolimod hydrochloride
NOVARTIS PHARMA AG
2012 Phase 3 EUCTR2011-005280-24-IT Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
Novartis Pharma Services AG
2015 Phase 2;Phase 3 EUCTR2011-005280-24-CZ Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Serbia;Spain;United Kingdom;United States
2013 Phase 2;Phase 3 EUCTR2011-005280-24-PL Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2013 Phase 2;Phase 3 EUCTR2011-005280-24-NL Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2012 Phase 2;Phase 3 EUCTR2011-005280-24-GR Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2012 Phase 2;Phase 3 EUCTR2011-005280-24-GB Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2012 Phase 2;Phase 3 EUCTR2011-005280-24-DE Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2012 Phase 2;Phase 3 EUCTR2011-005280-24-BE Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
Fludarabine
Kite, A Gilead Company
2026 Phase 1 NCT07304154 Australia;United States
Tongji Hospital
2026 Phase 1 NCT07526493 China
Fresh frozen plasma
University Medical Centre Ljubljana
2018 - NCT03801135 Slovenia
FTY720I
NOVARTIS PHARMA AG
2012 Phase 3 EUCTR2011-005280-24-IT Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
Novartis Pharma Services AG
2015 Phase 2;Phase 3 EUCTR2011-005280-24-CZ Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Serbia;Spain;United Kingdom;United States
2013 Phase 2;Phase 3 EUCTR2011-005280-24-PL Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2013 Phase 2;Phase 3 EUCTR2011-005280-24-NL Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2012 Phase 2;Phase 3 EUCTR2011-005280-24-GR Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2012 Phase 2;Phase 3 EUCTR2011-005280-24-GB Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2012 Phase 2;Phase 3 EUCTR2011-005280-24-ES Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2012 Phase 2;Phase 3 EUCTR2011-005280-24-DE Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2012 Phase 2;Phase 3 EUCTR2011-005280-24-BE Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
Gammanorm
Aarhus Unversity Hospital
2017 Phase 4 EUCTR2017-002024-24-DK Denmark
Gamunex-C
Grifols Therapeutics LLC
2026 Phase 3 NCT07540221 United States
Genome-wide association study
Istituto Clinico Humanitas
2022 - NCT06325878 Italy
Gilenya
Novartis Pharma Services AG
2012 Phase 2;Phase 3 EUCTR2011-005280-24-GR Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
Gilenya 0,5 MG Cápsulas duras
Novartis Pharma Services AG
2012 Phase 2;Phase 3 EUCTR2011-005280-24-ES Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
Group C meningococcal conjugate vaccine
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
H.P. acthar® GEL
Mamatha Pasnoor, MD
2015 Phase 2 NCT02574962 United States
HB-admscs
Hope Biosciences Research Foundation
2021 - NCT04825626 United States
HBM9161
Immunovant Sciences, GmbH
2023 Phase 2 EUCTR2022-002718-17-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-SE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-RO Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-NO Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-FI Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-DK Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-DE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-BG Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-BE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
Hematopoietic stem cell transplantation
Northwestern University
2005 Phase 2 NCT00278629 United States
Hidrocloruro DE fingolimod
Novartis Pharma Services AG
2012 Phase 2;Phase 3 EUCTR2011-005280-24-ES Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
Himan normal immunoglobulin
BAXTER S.P.A.
2018 Phase 3 EUCTR2014-005496-87-IT Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Hizentra
Aarhus University Hospital
2019 Phase 4 EUCTR2018-003592-34-DK Denmark
2013 Phase 2 EUCTR2013-001428-20-DK Denmark
Aarhus Unversity Hospital
2017 Phase 4 EUCTR2017-002024-24-DK Denmark
CSL BEHRING GMBH
2012 Phase 3 EUCTR2011-003448-28-IT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;Germany;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
CSL Behring
2022 - NCT04672733 France
CSL Behring GmbH
2015 Phase 3 EUCTR2013-004157-24-CZ Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2015 Phase 3 EUCTR2011-003448-28-PL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2015 - EUCTR2011-003448-28-LT Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2011-003448-28-EE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-004157-24-NL Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-IT Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-GB Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-004157-24-FI Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-ES Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-DE Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2012 Phase 3 EUCTR2011-003448-28-NL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-GB Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-FI Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-ES Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-DE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-BE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 - EUCTR2011-003448-28-AT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States
HL161BKN
Immunovant Sciences, GmbH
2023 Phase 2 EUCTR2022-002718-17-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-SE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-RO Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-NO Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-FI Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-DK Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-DE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-BG Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-BE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
Human immunoglobulin G
Aarhus University Hospital
2019 Phase 4 EUCTR2018-003592-34-DK Denmark
Aarhus Unversity Hospital
2017 Phase 4 EUCTR2017-002024-24-DK Denmark
Human normal immunoglobulin
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Aarhus University Hospital
2013 Phase 2 EUCTR2013-001428-20-DK Denmark
Aarhus University Hospital, Department of Neurology
2009 Phase 2 EUCTR2009-013930-25-DK Denmark
BAXALTA INNOVATIONS GMBH
2016 Phase 3 EUCTR2016-000374-37-IT Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
BAXTER S.P.A.
2018 Phase 3 EUCTR2014-005496-87-IT Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Baxalta Innovation GmbH
2016 Phase 3 EUCTR2014-005496-87-DE Argentina;Austria;Belgium;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Baxalta Innovations GmbH
2020 Phase 3 EUCTR2016-000374-37-HR Argentina;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2019 Phase 3 EUCTR2016-000374-37-PL Argentina;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2019 Phase 3 EUCTR2016-000374-37-DE Argentina;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Turkey;United Kingdom;United States
2019 Phase 3 EUCTR2014-005496-87-HR Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2017 Phase 3 EUCTR2016-000374-37-NO Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2016-000374-37-GR Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2016-000374-37-GB Argentina;Brazil;Canada;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2016-000374-37-ES Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2016-000374-37-DK Canada;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2016-000374-37-CZ Argentina;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2014-005496-87-PL Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2017 Phase 3 EUCTR2014-005496-87-AT Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2016-000374-37-FR Canada;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2016 Phase 3 EUCTR2014-005496-87-SK Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2014-005496-87-NO Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2014-005496-87-GR Austria;Belgium;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Netherlands;Norway;Peru;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2014-005496-87-DK Austria;Canada;Czech Republic;Denmark;Germany;Greece;Israel;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 Phase 3 EUCTR2014-005496-87-SE Argentina;Austria;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 - EUCTR2014-005496-87-GB Canada;Czech Republic;Denmark;Germany;Italy;Netherlands;Norway;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 Phase 3 EUCTR2014-005496-87-ES Austria;Canada;Croatia;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 Phase 3 EUCTR2014-005496-87-CZ Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Baxter Innovations GmbH
2009 - EUCTR2009-013841-27-DK Denmark
CSL BEHRING GMBH
2012 Phase 3 EUCTR2011-003448-28-IT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;Germany;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
CSL Behring GmbH
2015 Phase 3 EUCTR2013-004157-24-CZ Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2015 Phase 3 EUCTR2011-003448-28-PL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2015 - EUCTR2011-003448-28-LT Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2011-003448-28-EE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-004157-24-NL Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-IT Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-GB Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-004157-24-FI Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-ES Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-DE Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2012 Phase 3 EUCTR2011-003448-28-NL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-GB Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-FI Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-ES Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-DE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-BE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 - EUCTR2011-003448-28-AT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States
2010 - EUCTR2009-017672-24-FI Finland
2010 Phase 3 EUCTR2009-017672-24-BE Belgium;Finland
LFB BIOTECHNOLOGIES
2016 Phase 3 EUCTR2013-005558-31-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom
2015 Phase 3 EUCTR2013-005558-31-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom
2015 Phase 3 EUCTR2013-005558-31-FR France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
2015 Phase 3 EUCTR2013-005558-31-ES France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
2013 Phase 3 EUCTR2012-001996-34-FR France
Octapharma
- Phase 3 EUCTR2021-003200-40-Outside-EU/EEA United States
Rigshospitalet
2015 Phase 2 EUCTR2015-003453-18-DK Denmark
Teijin Pharma Limited
2014 Phase 3 JPRN-jRCT2080222422 Japan
2014 Phase 3 JPRN-jRCT2080222421 Japan
Human normal immunoglobulin FOR intravenous administration
LFB BIOTECHNOLOGIES
2016 Phase 3 EUCTR2013-005557-73-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom
2015 Phase 3 EUCTR2012-001995-12-IT France;Italy;Spain;United Kingdom
2014 Phase 3 EUCTR2013-005557-73-IT France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
2014 Phase 3 EUCTR2013-005557-73-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom
2014 Phase 3 EUCTR2013-005557-73-FR France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
2014 Phase 3 EUCTR2013-005557-73-ES France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
2013 Phase 3 EUCTR2012-001995-12-GB France;Italy;Spain;United Kingdom
2013 Phase 3 EUCTR2012-001995-12-FR France;Spain;United Kingdom
2013 Phase 3 EUCTR2012-001995-12-ES France;Spain;United Kingdom
Laboratoire français de Fractionnement et de Biotechnologies
2013 Phase 3 NCT01951924 France;Italy;Spain;United Kingdom
Hyaluronidase
Nishizawa Atsushi
2021 Phase 3 JPRN-jRCT2051210110 -
Hyqvia
Baxalta now part of Shire
2016 Phase 3 NCT02955355 Argentina;Brazil;Canada;Colombia;Czechia;Denmark;France;Germany;Greece;Italy;Mexico;Poland;Serbia;Slovakia;Spain;Turkey;United Kingdom;United States
2015 Phase 3 NCT02549170 Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Johannes Jakobsen
2016 Phase 2 NCT02556437 Denmark
Rigshospitalet
2015 Phase 2 EUCTR2015-003453-18-DK Denmark
Takeda
2025 Phase 3 NCT06747351 Argentina;Czechia;Denmark;Germany;Greece;Italy;Japan;Poland;Spain;Sweden;United States
UMC Utrecht
2016 Phase 3 EUCTR2015-000828-28-NL Netherlands
Hyqvia - 100 MG/ML - soluzione PER infusione - USO sottocutaneo - flaconcino (vetro) 300 ML E flaconcino (vetro) 15 ML - 1 flaconcino + 1 flaconcino
BAXTER S.P.A.
2018 Phase 3 EUCTR2014-005496-87-IT Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Hyqvia 100 MG/ML solution FOR infusion FOR subcutaneous USE
BAXALTA INNOVATIONS GMBH
2016 Phase 3 EUCTR2016-000374-37-IT Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
Baxalta Innovation GmbH
2016 Phase 3 EUCTR2014-005496-87-DE Argentina;Austria;Belgium;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Baxalta Innovations GmbH
2020 Phase 3 EUCTR2016-000374-37-HR Argentina;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2019 Phase 3 EUCTR2016-000374-37-PL Argentina;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2019 Phase 3 EUCTR2016-000374-37-DE Argentina;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Turkey;United Kingdom;United States
2019 Phase 3 EUCTR2014-005496-87-HR Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2017 Phase 3 EUCTR2016-000374-37-NO Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2016-000374-37-GR Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2016-000374-37-GB Argentina;Brazil;Canada;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2016-000374-37-ES Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2016-000374-37-DK Canada;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2016-000374-37-CZ Argentina;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2014-005496-87-PL Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2017 Phase 3 EUCTR2014-005496-87-AT Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2016-000374-37-FR Canada;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2016 Phase 3 EUCTR2014-005496-87-SK Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2014-005496-87-NO Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2014-005496-87-GR Austria;Belgium;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Netherlands;Norway;Peru;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2014-005496-87-DK Austria;Canada;Czech Republic;Denmark;Germany;Greece;Israel;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 Phase 3 EUCTR2014-005496-87-SE Argentina;Austria;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 - EUCTR2014-005496-87-GB Canada;Czech Republic;Denmark;Germany;Italy;Netherlands;Norway;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 Phase 3 EUCTR2014-005496-87-ES Austria;Canada;Croatia;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 Phase 3 EUCTR2014-005496-87-CZ Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
I10
LFB BIOTECHNOLOGIES
2016 Phase 3 EUCTR2013-005558-31-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom
2016 Phase 3 EUCTR2013-005557-73-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom
2015 Phase 3 EUCTR2013-005558-31-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom
I10E
LFB BIOTECHNOLOGIES
2015 Phase 3 EUCTR2013-005558-31-IT France;Germany;Italy;Mexico;Morocco;Spain;Turkey;United Kingdom
2015 Phase 3 EUCTR2013-005558-31-FR France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
2015 Phase 3 EUCTR2013-005558-31-ES France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
2015 Phase 3 EUCTR2012-001995-12-IT France;Italy;Spain;United Kingdom
2014 Phase 3 EUCTR2013-005557-73-IT France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
2014 Phase 3 EUCTR2013-005557-73-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom
2014 Phase 3 EUCTR2013-005557-73-FR France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
2014 Phase 3 EUCTR2013-005557-73-ES France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
2013 Phase 3 EUCTR2012-001995-12-GB France;Italy;Spain;United Kingdom
2013 Phase 3 EUCTR2012-001995-12-FR France;Spain;United Kingdom
2013 Phase 3 EUCTR2012-001995-12-ES France;Spain;United Kingdom
Laboratoire français de Fractionnement et de Biotechnologies
2015 Phase 3 NCT02317562 France;Italy;Spain;Tunisia;Turkey;United Kingdom
2015 Phase 3 NCT02293460 France;Italy;Morocco;Spain;Tunisia;Turkey;United Kingdom
2013 Phase 3 NCT01951924 France;Italy;Spain;United Kingdom
Igiv gammagard liquid/kiovig
Baxalta now part of Shire
2015 Phase 3 NCT02549170 Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Igiv gamunex®-C
Baxalta now part of Shire
2015 Phase 3 NCT02549170 Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Igpro10
CSL BEHRING GMBH
2012 Phase 3 EUCTR2011-003448-28-IT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;Germany;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
CSL Behring
2019 Phase 4 NCT03684018 Canada;United States
2012 Phase 3 NCT01545076 Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
CSL Behring GmbH
2015 Phase 3 EUCTR2011-003448-28-PL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2015 - EUCTR2011-003448-28-LT Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2011-003448-28-EE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-NL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-GB Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-FI Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-ES Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-DE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-BE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 - EUCTR2011-003448-28-AT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States
Igpro20
CSL Behring
2014 Phase 3 NCT02027701 Australia;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
2012 Phase 3 NCT01545076 Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
CSL Behring GmbH
2015 Phase 3 EUCTR2013-004157-24-CZ Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2015 Phase 3 EUCTR2011-003448-28-PL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2015 - EUCTR2011-003448-28-LT Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2011-003448-28-EE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-004157-24-NL Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-IT Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-GB Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-004157-24-FI Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-ES Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-DE Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2012 Phase 3 EUCTR2011-003448-28-NL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-GB Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-FI Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-ES Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-DE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-BE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 - EUCTR2011-003448-28-AT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States
Igvena*FL 200ML 10G+SET
KEDRION
2007 - EUCTR2005-001136-76-IT Italy
Imeroprubart
Immunovant Sciences GmbH
2025 Phase 2 NCT07032662 Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Colombia;Denmark;Estonia;Finland;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey (Türkiye);United Kingdom;United States
Immune globulin
Baxalta now part of Shire
2008 Phase 3 NCT00666263 Canada;Denmark;Netherlands;Poland;United States
National Center for Research Resources (NCRR)
1992 Phase 3 NCT00004772 -
Nishizawa Atsushi
2021 Phase 3 JPRN-jRCT2051210110 -
University of South Florida
2014 - NCT02465359 United States
Immune globulin (human) 10% solution FOR intravenous administration
Kedrion S.p.A.
2026 Phase 3 NCT06752356 United States
Immune globulin 10% intravenous solution
Vera Bril
2017 Phase 3 NCT03166527 Canada
Immune globulin IV (human), 10% caprylate/chromatography purified
Grifols Therapeutics Inc.
2004 Phase 3 NCT00220740 Argentina;Canada;Czech Republic;Former Serbia and Montenegro;Germany;Israel;Italy;Mexico;Poland;Serbia;United States
Immunoadsorption
University of Ulm
2023 Phase 2 NCT04881682 Germany
Immunoglobulin
University of Aarhus
2020 Phase 4 NCT04589299 Denmark
Yamamoto Akihiko
2024 Phase 3 JPRN-jRCT2051240028 -
Immunoglobulin G
CSL Behring AG
2008 Phase 2 EUCTR2007-000710-37-GB Germany;Italy;United Kingdom
2007 - EUCTR2007-000710-37-DE Germany;Italy;United Kingdom
CSL Behring GmbH
2010 - EUCTR2009-017672-24-FI Finland
2010 Phase 3 EUCTR2009-017672-24-BE Belgium;Finland
Octapharma Pharmazeutika Produktionsges.m.b.H.
2017 Phase 3 EUCTR2015-005443-14-SE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-PL Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-HU Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-DK Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-DE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-CZ Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-BG Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
Immunoglobulin perfusion
Centre Hospitalier Universitaire de Saint Etienne
2004 Phase 3 NCT01349270 France
Immunoglobulina normale umana
BAXTER S.P.A.
2018 Phase 3 EUCTR2014-005496-87-IT Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Immunoglobulina umana normale
BAXALTA INNOVATIONS GMBH
2016 Phase 3 EUCTR2016-000374-37-IT Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
Immunoglobulina umana normale PER somministrazione endovenosa
LFB BIOTECHNOLOGIES
2015 Phase 3 EUCTR2013-005558-31-IT France;Germany;Italy;Mexico;Morocco;Spain;Turkey;United Kingdom
Immunoglobuline G
Octapharma AG
2011 Phase 2;Phase 3 EUCTR2009-017805-13-CZ Bulgaria;Czech Republic
2011 - EUCTR2009-017805-13-BG Bulgaria;Czech Republic;India;Mexico;Poland;Romania;Serbia;Ukraine
2010 Phase 2;Phase 3 EUCTR2009-017805-13-RO Bulgaria;Czech Republic;Romania
Immunoglobuline humaine normale
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2007 - EUCTR2006-006392-21-FR France
Immunoglobulins
CSL Behring AG
2007 - EUCTR2007-000710-37-IT Germany;Italy;United Kingdom
KEDRION
2007 - EUCTR2005-001136-76-IT Italy
Rigshospitalet, Denmark
2014 - NCT02111590 Denmark
University of Ulm
2023 Phase 2 NCT04881682 Germany
IMVT-1401
Immunovant Sciences, GmbH
2023 Phase 2 EUCTR2022-002718-17-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-SE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-RO Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-NO Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-FI Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-DK Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-DE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-BG Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-BE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
Interferon BETA-1A
Biogen Idec
2004 Phase 2 NCT00099489 Australia;Canada;United Kingdom;United States
Intratect
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Intravenous gammaglobulin
University of Aarhus
2005 - NCT00305266 Denmark
Intravenous immune globulin G
Rutgers, The State University of New Jersey
2022 Phase 1 NCT05584631 United States
Intravenous immunoglobulin
CIDP Study Group
2006 - JPRN-UMIN000000674 Japan
National Institute of Neurological Disorders and Stroke (NINDS)
1990 Phase 2 NCT00001287 United States
University of Aarhus
2005 Phase 2 NCT00268788 Denmark
University of Minnesota
2015 - NCT02414490 United States
University of Toronto
2015 Phase 4 NCT02372149 Canada
argenx
2024 Phase 3 NCT06742190 Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Latvia;Lithuania;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;Slovenia;Spain;Switzerland;United Kingdom;United States
Iqymune
LFB BIOTECHNOLOGIES
2016 Phase 3 EUCTR2013-005558-31-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom
2016 Phase 3 EUCTR2013-005557-73-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom
2015 Phase 3 EUCTR2013-005558-31-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom
2014 Phase 3 EUCTR2013-005557-73-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom
Ivig
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Assistance Publique - Hôpitaux de Paris
2015 - NCT02404298 France
Kamino Eriko
2025 Phase 3 JPRN-jRCT2051250110 Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Korea;Spain;Sweden;Switzerland;Tunisia;Turkey;USA;United Kingdom
Narita Takanori
2025 Phase 3 JPRN-jRCT2061250020 Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Italy;Japan;Korea;Latvia;Lithuania;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;Slovenia;Spain;Sweden;Switzerland;United Kingdom;United States
National Institute of Neurological Disorders and Stroke (NINDS)
1990 Phase 2 NCT00001287 United States
Obara Kentaro
2024 Phase 3 JPRN-jRCT2031240206 Argentina;Belgium;Brazil;Canada;China;Czechia;Denmark;Germany;Hungary;Israel;Japan;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United States
Sanofi
2024 Phase 3 NCT06290141 Argentina;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Mexico;Norway;Portugal;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey (Türkiye);United Kingdom;United States
University of Toronto
2015 Phase 4 NCT02372149 Canada
argenx
2025 Phase 3 NCT06920004 Argentina;Austria;Czechia;Estonia;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Slovenia;South Korea;Spain;Sweden;Switzerland;Turkey (Türkiye);United Kingdom;United States
2024 Phase 3 NCT06742190 Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Latvia;Lithuania;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;Slovenia;Spain;Switzerland;United Kingdom;United States
JNJ-80202135
Tominaga Yushin
2022 Phase 2-3 JPRN-jRCT2041220037 Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Greece;Italy;Japan;Korea Republic Of;Mexico;Poland;Portugal;Spain;Taiwan;United Kingdom Of Great Britain;United States Of America
KINE-101
Kine Sciences Co., Ltd.
2024 Phase 1 NCT07343310 South Korea
Kiovig
Erasmus MC
2014 Phase 4 EUCTR2013-004988-32-NL Netherlands
2014 Phase 4 EUCTR2012-005150-34-NL Netherlands
LFB BIOTECHNOLOGIES
2015 Phase 3 EUCTR2012-001995-12-IT France;Italy;Spain;United Kingdom
2013 Phase 3 EUCTR2012-001995-12-GB France;Italy;Spain;United Kingdom
2013 Phase 3 EUCTR2012-001995-12-FR France;Spain;United Kingdom
2013 Phase 3 EUCTR2012-001995-12-ES France;Spain;United Kingdom
Laboratoire français de Fractionnement et de Biotechnologies
2013 Phase 3 NCT01951924 France;Italy;Spain;United Kingdom
Kiovig - 100 MG/ML soluzione PER infusione USO intravenoso flacone vetro 1 G/10 ML 1 flacone
BAXTER S.P.A.
2018 Phase 3 EUCTR2014-005496-87-IT Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Kiovig 100 MG/ML solution FOR infusion
Baxalta Innovation GmbH
2016 Phase 3 EUCTR2014-005496-87-DE Argentina;Austria;Belgium;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Baxalta Innovations GmbH
2019 Phase 3 EUCTR2014-005496-87-HR Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2017 Phase 3 EUCTR2014-005496-87-PL Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2017 Phase 3 EUCTR2014-005496-87-AT Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2014-005496-87-SK Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2014-005496-87-NO Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2014-005496-87-GR Austria;Belgium;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Netherlands;Norway;Peru;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2014-005496-87-DK Austria;Canada;Czech Republic;Denmark;Germany;Greece;Israel;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 Phase 3 EUCTR2014-005496-87-SE Argentina;Austria;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 - EUCTR2014-005496-87-GB Canada;Czech Republic;Denmark;Germany;Italy;Netherlands;Norway;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 Phase 3 EUCTR2014-005496-87-ES Austria;Canada;Croatia;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 Phase 3 EUCTR2014-005496-87-CZ Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Baxter Innovations GmbH
2009 - EUCTR2009-013841-27-DK Denmark
KITE-363
Kite, A Gilead Company
2026 Phase 1 NCT07304154 Australia;United States
Laboratory biomarker analysis
Fred Hutchinson Cancer Center
2008 Phase 2 NCT00716066 United States
Lipoic acid
Oregon Health and Science University
2009 Phase 2 NCT00962429 United States
Lumbar puncture
University of Aarhus
2015 - NCT02271724 Denmark
Lymphodepleting conditioning
Tongji Hospital
2025 Early Phase 1 NCT07337785 China
M281/JNJ-80202135
Janssen-Cilag International NV
2022 Phase 2;Phase 3 EUCTR2021-003234-37-SK Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
2022 Phase 2;Phase 3 EUCTR2021-003234-37-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
2022 Phase 2;Phase 3 EUCTR2021-003234-37-PL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
2022 Phase 2;Phase 3 EUCTR2021-003234-37-FR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
2022 Phase 2;Phase 3 EUCTR2021-003234-37-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
2022 Phase 2;Phase 3 EUCTR2021-003234-37-CZ Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
Mabthera - 1 fiala 500 MG 50 ML
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 2 EUCTR2018-001347-31-IT Italy
2018 Phase 3 EUCTR2017-005034-36-IT Italy
Maxtrex tablets
Guy's & St Thomas's NHS Foundation Trust
2006 Phase 4 EUCTR2005-003382-16-BE Belgium;Italy;United Kingdom
2005 Phase 4 EUCTR2005-003382-16-GB Belgium;Italy;United Kingdom
ISTITUTO CLINICO HUMANITAS
2006 - EUCTR2005-003382-16-IT Italy;United Kingdom
MD1003
MEDDAY PHARMACEUTICALS
2016 Phase 2 EUCTR2015-001150-15-FR France
MedDay Pharmaceuticals SA
2016 Phase 2 NCT02967679 France
Melphalan
Fred Hutchinson Cancer Center
2008 Phase 2 NCT00716066 United States
Menjugate
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Methotrexate
Guy's & St Thomas's NHS Foundation Trust
2006 Phase 4 EUCTR2005-003382-16-BE Belgium;Italy;United Kingdom
2005 Phase 4 EUCTR2005-003382-16-GB Belgium;Italy;United Kingdom
ISTITUTO CLINICO HUMANITAS
2006 - EUCTR2005-003382-16-IT Italy;United Kingdom
Methylprednisolone
Academic Medical Centre, Amsterdam, NL
2019 Phase 3 EUCTR2017-002511-34-GB Netherlands;United Kingdom
Academisch Medisch Centrum
2018 Phase 3 EUCTR2017-002511-34-NL Netherlands;United Kingdom
Metilprednisolone sodio succinato
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2017-005034-36-IT Italy
N. meningitidis group C polysaccharide
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Newgam
Octapharma
2011 Phase 2/Phase 3 NCT01225276 -
Octapharma AG
2011 Phase 2;Phase 3 EUCTR2009-017805-13-CZ Bulgaria;Czech Republic
2011 - EUCTR2009-017805-13-BG Bulgaria;Czech Republic;India;Mexico;Poland;Romania;Serbia;Ukraine
2010 Phase 2;Phase 3 EUCTR2009-017805-13-RO Bulgaria;Czech Republic;Romania
Octapharma Pharmazeutika Produktionsges.m.b.H.
2017 Phase 3 EUCTR2015-005443-14-SE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-PL Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-HU Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-DK Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-DE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-CZ Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-BG Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
Nipocalimab
Janssen Research & Development, LLC
2022 Phase 2/Phase 3 NCT05327114 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Mexico;Poland;Portugal;Romania;Slovakia;South Africa;South Korea;Spain;Taiwan;United Kingdom;United States
Janssen-Cilag International NV
2022 Phase 2;Phase 3 EUCTR2021-003234-37-SK Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
2022 Phase 2;Phase 3 EUCTR2021-003234-37-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
2022 Phase 2;Phase 3 EUCTR2021-003234-37-PL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
2022 Phase 2;Phase 3 EUCTR2021-003234-37-FR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
2022 Phase 2;Phase 3 EUCTR2021-003234-37-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
2022 Phase 2;Phase 3 EUCTR2021-003234-37-CZ Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
Tominaga Yushin
2022 Phase 2-3 JPRN-jRCT2041220037 Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Greece;Italy;Japan;Korea Republic Of;Mexico;Poland;Portugal;Spain;Taiwan;United Kingdom Of Great Britain;United States Of America
NPB-01
Nihon Pharmaceutical Co., Ltd
2013 Phase 3 NCT01827072 Japan
2013 Phase 3 NCT01824251 Japan
NT3 blood draw
Zarife Sahenk
2027 - NCT05011006 United States
NVG-2089
Nuvig Therapeutics, Inc.
2025 Phase 2 NCT07027111 United States
Panzyga
Octapharma
2023 Phase 3 NCT04929236 United States
- Phase 3 EUCTR2021-003200-40-Outside-EU/EEA United States
Octapharma Pharmazeutika Produktionsges.m.b.H.
2017 Phase 3 EUCTR2015-005443-14-SE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-PL Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-HU Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-DK Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-DE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-CZ Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-BG Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
Paracetamolo
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2017-005034-36-IT Italy
Peripheral blood stem cell transplantation
Fred Hutchinson Cancer Center
2008 Phase 2 NCT00716066 United States
Prednisolone
AMC Medical research BV
2006 - EUCTR2004-002783-24-GB United Kingdom
Prednisone
Centre Hospitalier Universitaire de Saint Etienne
2004 Phase 3 NCT01349270 France
Fred Hutchinson Cancer Center
2008 Phase 2 NCT00716066 United States
Prevenar 13 sospensione PER iniezione
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Privigen
Aarhus University Hospital
2019 Phase 4 EUCTR2018-003592-34-DK Denmark
2013 Phase 2 EUCTR2013-001428-20-DK Denmark
CSL Behring GmbH
2010 - EUCTR2009-017672-24-FI Finland
2010 Phase 3 EUCTR2009-017672-24-BE Belgium;Finland
Rhuph20
Baxalta now part of Shire
2015 Phase 3 NCT02549170 Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Nishizawa Atsushi
2021 Phase 3 JPRN-jRCT2051210110 -
UMC Utrecht
2016 - NCT02885259 Netherlands
Riliprubart
Huashan Hospital, Fudan University
2025 Phase 3 ChiCTR2500108198 China
Obara Kentaro
2025 Phase 3 JPRN-jRCT2031240109 Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Mexico;Netherlands;Poland;Portugal;Republic of Korea;Spain;Sweden;Taiwan;Turkey;United States
2024 Phase 3 JPRN-jRCT2031240206 Argentina;Belgium;Brazil;Canada;China;Czechia;Denmark;Germany;Hungary;Israel;Japan;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United States
Sanofi
2025 Phase 3 NCT06859099 Argentina;Brazil;Canada;Chile;China;Czechia;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Serbia;South Korea;Spain;Sweden;Turkey (Türkiye);United States
2024 Phase 3 NCT06290141 Argentina;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Mexico;Norway;Portugal;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey (Türkiye);United Kingdom;United States
2024 Phase 3 NCT06290128 Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Mexico;Netherlands;Poland;Portugal;South Korea;Spain;Sweden;Switzerland;Taiwan;Turkey (Türkiye);United States
Ripertamab
Second Affiliated Hospital of Army Medical University
2026 - ChiCTR2600120227 China
Zhongming Qiu
2025 Phase 3 NCT06858722 -
Rituximab
Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC)
2024 Phase 3 NCT06714838 Netherlands
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 2 EUCTR2018-001347-31-IT Italy
2018 Phase 3 EUCTR2017-005034-36-IT Italy
Iijima Masahiro
2019 Phase 2 JPRN-jRCT2041180037 -
Istituto Clinico Humanitas
2019 Phase 3 NCT06325943 Italy
2019 Phase 2 NCT05877040 Italy
Katsuno Masahisa
2021 Phase 2 JPRN-jRCTs041210046 -
Nagoya University
2019 Phase 2 NCT03864185 Japan
Nagoya University Hospital
2019 Phase 2 JPRN-UMIN000035753 Japan
University of Kansas Medical Center
2025 Phase 2 NCT04480450 -
Rozanolixizumab
UCB Biopharma S.P.R.L.
2019 Phase 2 NCT03861481 Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
UCB Biopharma SPRL
2020 Phase 2 EUCTR2018-004392-12-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2020 Phase 2 EUCTR2018-004392-12-DE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2018-004392-12-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2018-004392-12-FR Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2018-004392-12-ES Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2018-004392-12-DK Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-FR Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-ES Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-DK Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-DE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
UCB Biopharma SRL
2021 - NCT05014724 -
2019 Phase 2 NCT04051944 Belgium;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2018-004392-12-BE Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-BE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
RVG 51680
Department of Neurology, Academic Medical Center
2014 - EUCTR2013-005363-52-NL Netherlands
RVG 56083
Academisch Medisch Centrum
2018 Phase 3 EUCTR2017-002511-34-NL Netherlands;United Kingdom
RVT-1401
Immunovant Sciences, GmbH
2023 Phase 2 EUCTR2022-002718-17-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-SE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-RO Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-NO Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-FI Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-DK Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-DE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-BG Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-BE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
SAR445088
Bioverativ, a Sanofi company
2021 Phase 2 NCT04658472 Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain;United States
Obara Kentaro
2025 Phase 3 JPRN-jRCT2031240109 Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Mexico;Netherlands;Poland;Portugal;Republic of Korea;Spain;Sweden;Taiwan;Turkey;United States
2024 Phase 3 JPRN-jRCT2031240206 Argentina;Belgium;Brazil;Canada;China;Czechia;Denmark;Germany;Hungary;Israel;Japan;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United States
Sanofi-Aventis Recherche & Développement
2021 Phase 2 EUCTR2020-004006-54-PL Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain
2021 Phase 2 EUCTR2020-004006-54-NL Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain
2021 Phase 2 EUCTR2020-004006-54-DE Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain
SC investigational needle sets
Takeda
2025 Phase 3 NCT06747351 Argentina;Czechia;Denmark;Germany;Greece;Italy;Japan;Poland;Spain;Sweden;United States
Sodium chloride
Academic Medical Centre, Amsterdam, NL
2019 Phase 3 EUCTR2017-002511-34-GB Netherlands;United Kingdom
Academisch Medisch Centrum
2018 Phase 3 EUCTR2017-002511-34-NL Netherlands;United Kingdom
Department of Neurology, Academic Medical Center
2014 - EUCTR2013-005363-52-NL Netherlands
Soliris
Greater Glasgow and Clyde NHS Board and The University Of Glasgow
2009 - EUCTR2008-005748-18-GB United Kingdom
Solu medrol - 125 MG/2 ML polvere E solvente PER soluzione iniettabile 1 flacone A doppia camera DA 125 MG/2 ML
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2017-005034-36-IT Italy
Subcutaneous immune globulin G
Rutgers, The State University of New Jersey
2022 Phase 1 NCT05584631 United States
Subcutaneous immunoglobulin
University of Aarhus
2010 Phase 2 NCT01017159 Denmark
2005 Phase 2 NCT00268788 Denmark
Subcuvia
Aarhus University Hospital, Department of Neurology
2009 Phase 2 EUCTR2009-013930-25-DK Denmark
Aarhus Unversity Hospital
2017 Phase 4 EUCTR2017-002024-24-DK Denmark
Johannes Jakobsen
2016 Phase 2 NCT02556437 Denmark
Rigshospitalet
2015 Phase 2 EUCTR2015-003453-18-DK Denmark
Syngeneic bone marrow transplantation
Fred Hutchinson Cancer Center
2008 Phase 2 NCT00716066 United States
TAK-411
Takeda
2025 Phase 2 NCT06798012 Canada;Colombia;United States
TAK-771
Nishizawa Atsushi
2021 Phase 3 JPRN-jRCT2051210110 -
Takeda
2022 Phase 3 NCT05084053 Japan
TAK-881
Takeda
2025 Phase 3 NCT06747351 Argentina;Czechia;Denmark;Germany;Greece;Italy;Japan;Poland;Spain;Sweden;United States
Tegeline 50MG/ML
LFB BIOTECHNOLOGIES
2013 Phase 3 EUCTR2012-001996-34-FR France
Telitacicept
Sichuan Academy of Medical Sciences
2025 - NCT07597733 China
Trimeton - 10 MG/1 ML soluzione iniettabile 5 fiale 1 ML
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2017-005034-36-IT Italy
TéGéline
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2007 - EUCTR2006-006392-21-FR France
Ucar T-cell
Tianjin Huanhu Hospital
2025 Early Phase 1 NCT06939166 China
UCB7665
UCB Biopharma SPRL
2020 Phase 2 EUCTR2018-004392-12-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2020 Phase 2 EUCTR2018-004392-12-DE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2018-004392-12-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2018-004392-12-FR Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2018-004392-12-ES Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2018-004392-12-DK Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-FR Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-ES Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-DK Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-DE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
UCB Biopharma SRL
2019 Phase 2 EUCTR2018-004392-12-BE Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-BE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
Universal bcma CAR-T
Xuanwu Hospital, Beijing
2025 Early Phase 1 NCT06485232 China
Universal CD19 CAR-?DT cell injection
Tongji Hospital
2026 Phase 1 NCT07526493 China
Universal CD19 CAR-T
Xuanwu Hospital, Beijing
2025 Early Phase 1 NCT06485232 China
Vaccino pneumococcico saccaridico
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Vivaglobin
CSL Behring
2007 Phase 2 NCT00701662 Germany;Italy;Switzerland;United Kingdom
CSL Behring AG
2008 Phase 2 EUCTR2007-000710-37-GB Germany;Italy;United Kingdom
2007 - EUCTR2007-000710-37-IT Germany;Italy;United Kingdom
2007 - EUCTR2007-000710-37-DE Germany;Italy;United Kingdom
Xembify
Grifols Therapeutics LLC
2026 Phase 3 NCT07540221 United States
University of Toronto
2015 Phase 4 NCT02372149 Canada
10% liquid formulation OF human immunoglobulin
CSL Behring
2010 Phase 3 NCT01184846 Belgium;Finland;France;Germany;Poland
ACT-HIB
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Alemtuzumab infusion
Johns Hopkins University
2012 Phase 4 NCT01757574 United States
ANTI-C5 antibody
Greater Glasgow and Clyde NHS Board and The University Of Glasgow
2009 - EUCTR2008-005748-18-GB United Kingdom
ANTI-thymocyte globulin
Fred Hutchinson Cancer Center
2008 Phase 2 NCT00716066 United States
ARGX-113
ARGENX BV
2020 Phase 2 EUCTR2019-003107-35-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
argenx BVBA
2021 Phase 2 EUCTR2019-003107-35-RO Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003107-35-CZ Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003107-35-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003076-39-RO Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003076-39-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-DE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-BE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-PL Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-LV Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-DE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-BE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
ARGX-117
argenx
2023 Phase 2 NCT05405361 Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 NCT05225675 Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
ARGX-117 IV
ARGENX BV
2022 Phase 2 EUCTR2021-004998-32-IT Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
argenx BV
2023 Phase 2 EUCTR2021-004998-32-DE Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2023 Phase 2 EUCTR2021-004998-32-AT Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-004998-32-NL Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-004998-32-FR Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-004998-32-ES Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-004998-32-BE Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-003302-50-PL Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-003302-50-NL Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-003302-50-FR Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-003302-50-ES Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-003302-50-DE Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-003302-50-BE Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2022 Phase 2 EUCTR2021-003302-50-AT Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Autologous hematopoietic stem cell transplantation
Fred Hutchinson Cancer Center
2008 Phase 2 NCT00716066 United States
BAFF-R cart
Tianjin Medical University General Hospital
2025 Phase 1/Phase 2 NCT07022197 China
Batoclimab
Immunovant Sciences GmbH
2025 Phase 2 NCT07188844 Argentina;Belgium;Brazil;Germany;Greece;Italy;Poland;Romania;Serbia;Slovakia;United States
Immunovant Sciences, GmbH
2023 Phase 2 EUCTR2022-002718-17-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-SE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-RO Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-NO Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-FI Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-DK Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-DE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-BG Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-BE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
Batoclimab 340 MG SC weekly
Immunovant Sciences GmbH
2022 Phase 2 NCT05581199 Argentina;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Italy;Korea, Republic of;Norway;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
Batoclimab 680 milligrams (MG) subcutaneous (SC) weekly
Immunovant Sciences GmbH
2022 Phase 2 NCT05581199 Argentina;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Italy;Korea, Republic of;Norway;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
BIVV020
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 2 EUCTR2020-004006-54-IT Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain;United Kingdom;United States
Sanofi-Aventis Recherche & Développement
2021 Phase 2 EUCTR2020-004006-54-PL Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain
2021 Phase 2 EUCTR2020-004006-54-NL Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain
2021 Phase 2 EUCTR2020-004006-54-FR France;Germany;Italy;Netherlands;Poland
2021 Phase 2 EUCTR2020-004006-54-DE Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain
Blood sample
University of Aarhus
2015 - NCT02271724 Denmark
Blood sampling
Centre Hospitalier Universitaire de Nimes
2021 Early Phase 1 NCT04742374 France
Carmustine
Fred Hutchinson Cancer Center
2008 Phase 2 NCT00716066 United States
CD19/BCMA-targeted CAR-T cells
Tongji Hospital
2025 Early Phase 1 NCT07337785 China
Clairyg 50 MG/ML
LFB BIOTECHNOLOGIES
2013 Phase 3 EUCTR2012-001996-34-FR France
Clairyg 50MG/ML
LFB BIOTECHNOLOGIES
2013 Phase 3 EUCTR2012-001996-34-FR France
Claseprubart
Dianthus Therapeutics
2025 Phase 3 NCT06858579 Argentina;Australia;Belgium;Brazil;Bulgaria;China;Colombia;Croatia;Denmark;France;Georgia;Germany;Israel;Italy;Latvia;Malaysia;Netherlands;North Macedonia;Philippines;Poland;Romania;Serbia;South Korea;Spain;Thailand;United Kingdom;United States
2024 Phase 2 NCT06537999 Denmark;France;Italy;Netherlands;North Macedonia;Poland;Serbia;Spain;United Kingdom;United States
Clorfenamina maleato
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2017-005034-36-IT Italy
Conventional therapy
Sichuan Academy of Medical Sciences
2025 - NCT07597733 China
CT103A cells
Tongji Hospital
2020 Early Phase 1 NCT04561557 China
Cyclophosphamide
Kite, A Gilead Company
2026 Phase 1 NCT07304154 Australia;United States
Stony Brook University
2003 Phase 2 NCT01236456 United States
Tongji Hospital
2026 Phase 1 NCT07526493 China
Cyclophosphamide and fludarabine
Tongji Hospital
2020 Early Phase 1 NCT04561557 China
Cyclosporine
CIDP Study Group
2006 - JPRN-UMIN000000674 Japan
Cytarabine
Fred Hutchinson Cancer Center
2008 Phase 2 NCT00716066 United States
D-biotin
MEDDAY PHARMACEUTICALS
2016 Phase 2 EUCTR2015-001150-15-FR France
Dexamethasone
AMC Medical research BV
2006 - EUCTR2004-002783-24-GB United Kingdom
Eculizumab
Greater Glasgow and Clyde NHS Board and The University Of Glasgow
2009 - EUCTR2008-005748-18-GB United Kingdom
Efgartigimod
The First Affiliated Hospital of Chongqing Medical University.
2025 - ChiCTR2600119272 China
argenx
2023 - NCT06299748 Germany;Italy;Spain;United States
Efgartigimod alfa
ARGENX BV
2020 Phase 2 EUCTR2019-003107-35-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
argenx BVBA
2021 Phase 2 EUCTR2019-003107-35-RO Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003107-35-CZ Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003107-35-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003076-39-RO Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003076-39-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-DE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-BE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-PL Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-LV Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-DE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-BE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Efgartigimod PH20 SC
ARGENX BV
2020 Phase 2 EUCTR2019-003107-35-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
Tsuruyama Eri
2021 Phase 2 JPRN-jRCT2051210001 Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russia;Serbia;Spain;UK;US;Ukraine
2021 Phase 2 JPRN-jRCT2051200151 Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russia;Serbia;Spain;UK;US;Ukraine
argenx
2025 - NCT07264426 Germany;United States
2024 Phase 4 NCT06637072 United States
2022 - NCT04777734 Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United States
2020 Phase 2 NCT04280718 Austria;Belgium;Bulgaria;China;Czechia;Denmark;France;Georgia;Germany;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russia;Serbia;Spain;Taiwan;Turkey (Türkiye);Ukraine;United Kingdom;United States
argenx BVBA
2021 Phase 2 EUCTR2019-003107-35-RO Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003107-35-CZ Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003107-35-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003076-39-RO Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2019-003076-39-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-DE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003107-35-BE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-PL Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-LV Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-GB Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-DE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 2 EUCTR2019-003076-39-BE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Efgartigimod PH20 SC IN stage B
argenx
2020 Phase 2 NCT04281472 Austria;Belgium;Bulgaria;China;Czechia;Denmark;France;Georgia;Germany;Hungary;Israel;Italy;Japan;Latvia;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Empasiprubart
argenx
2025 Phase 3 NCT06920004 Argentina;Austria;Czechia;Estonia;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Slovenia;South Korea;Spain;Sweden;Switzerland;Turkey (Türkiye);United Kingdom;United States
2024 Phase 3 NCT06742190 Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Latvia;Lithuania;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;Slovenia;Spain;Switzerland;United Kingdom;United States
Empasiprubart IV
Kamino Eriko
2026 Phase 3 JPRN-jRCT2021250030 Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Korea;Spain
2025 Phase 3 JPRN-jRCT2051250110 Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Korea;Spain;Sweden;Switzerland;Tunisia;Turkey;USA;United Kingdom
Narita Takanori
2025 Phase 3 JPRN-jRCT2061250020 Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Italy;Japan;Korea;Latvia;Lithuania;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;Slovenia;Spain;Sweden;Switzerland;United Kingdom;United States
argenx
2026 Phase 2/Phase 3 NCT07638566 -
2026 Phase 1 NCT07610564 -
2025 Phase 3 NCT07091630 Argentina;Austria;Bulgaria;China;Czechia;Denmark;Estonia;France;Georgia;Greece;Italy;Japan;Moldova;Poland;Romania;Singapore;Slovakia;South Korea;United Kingdom;United States
Etoposide
Fred Hutchinson Cancer Center
2008 Phase 2 NCT00716066 United States
Fampridine
Department of Neurology, Odense University Hospital
2020 Phase 2 EUCTR2020-002438-34-DK Denmark
Fampyra
Department of Neurology, Odense University Hospital
2020 Phase 2 EUCTR2020-002438-34-DK Denmark
Fibrinogen concentrate
University Medical Centre Ljubljana
2018 - NCT03801135 Slovenia
Fingolimod
Novartis Pharmaceuticals
2012 Phase 3 NCT01625182 Australia;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
Tanabe Pharma Corporation, Novartis Pharma K.K.
2012 Phase 3 JPRN-jRCT2080221916 -
Fingolimod hydrochloride
NOVARTIS PHARMA AG
2012 Phase 3 EUCTR2011-005280-24-IT Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
Novartis Pharma Services AG
2015 Phase 2;Phase 3 EUCTR2011-005280-24-CZ Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Serbia;Spain;United Kingdom;United States
2013 Phase 2;Phase 3 EUCTR2011-005280-24-PL Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2013 Phase 2;Phase 3 EUCTR2011-005280-24-NL Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2012 Phase 2;Phase 3 EUCTR2011-005280-24-GR Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2012 Phase 2;Phase 3 EUCTR2011-005280-24-GB Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2012 Phase 2;Phase 3 EUCTR2011-005280-24-DE Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2012 Phase 2;Phase 3 EUCTR2011-005280-24-BE Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
Fludarabine
Kite, A Gilead Company
2026 Phase 1 NCT07304154 Australia;United States
Tongji Hospital
2026 Phase 1 NCT07526493 China
Fresh frozen plasma
University Medical Centre Ljubljana
2018 - NCT03801135 Slovenia
FTY720I
NOVARTIS PHARMA AG
2012 Phase 3 EUCTR2011-005280-24-IT Australia;Belgium;Canada;Czech Republic;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
Novartis Pharma Services AG
2015 Phase 2;Phase 3 EUCTR2011-005280-24-CZ Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Serbia;Spain;United Kingdom;United States
2013 Phase 2;Phase 3 EUCTR2011-005280-24-PL Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2013 Phase 2;Phase 3 EUCTR2011-005280-24-NL Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2012 Phase 2;Phase 3 EUCTR2011-005280-24-GR Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2012 Phase 2;Phase 3 EUCTR2011-005280-24-GB Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2012 Phase 2;Phase 3 EUCTR2011-005280-24-ES Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2012 Phase 2;Phase 3 EUCTR2011-005280-24-DE Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
2012 Phase 2;Phase 3 EUCTR2011-005280-24-BE Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
Gammanorm
Aarhus Unversity Hospital
2017 Phase 4 EUCTR2017-002024-24-DK Denmark
Gamunex-C
Grifols Therapeutics LLC
2026 Phase 3 NCT07540221 United States
Genome-wide association study
Istituto Clinico Humanitas
2022 - NCT06325878 Italy
Gilenya
Novartis Pharma Services AG
2012 Phase 2;Phase 3 EUCTR2011-005280-24-GR Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
Gilenya 0,5 MG Cápsulas duras
Novartis Pharma Services AG
2012 Phase 2;Phase 3 EUCTR2011-005280-24-ES Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
Group C meningococcal conjugate vaccine
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
H.P. acthar® GEL
Mamatha Pasnoor, MD
2015 Phase 2 NCT02574962 United States
HB-admscs
Hope Biosciences Research Foundation
2021 - NCT04825626 United States
HBM9161
Immunovant Sciences, GmbH
2023 Phase 2 EUCTR2022-002718-17-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-SE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-RO Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-NO Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-FI Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-DK Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-DE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-BG Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-BE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
Hematopoietic stem cell transplantation
Northwestern University
2005 Phase 2 NCT00278629 United States
Hidrocloruro DE fingolimod
Novartis Pharma Services AG
2012 Phase 2;Phase 3 EUCTR2011-005280-24-ES Australia;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;United Kingdom;United States
Himan normal immunoglobulin
BAXTER S.P.A.
2018 Phase 3 EUCTR2014-005496-87-IT Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Hizentra
Aarhus University Hospital
2019 Phase 4 EUCTR2018-003592-34-DK Denmark
2013 Phase 2 EUCTR2013-001428-20-DK Denmark
Aarhus Unversity Hospital
2017 Phase 4 EUCTR2017-002024-24-DK Denmark
CSL BEHRING GMBH
2012 Phase 3 EUCTR2011-003448-28-IT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;Germany;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
CSL Behring
2022 - NCT04672733 France
CSL Behring GmbH
2015 Phase 3 EUCTR2013-004157-24-CZ Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2015 Phase 3 EUCTR2011-003448-28-PL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2015 - EUCTR2011-003448-28-LT Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2011-003448-28-EE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-004157-24-NL Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-IT Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-GB Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-004157-24-FI Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-ES Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-DE Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2012 Phase 3 EUCTR2011-003448-28-NL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-GB Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-FI Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-ES Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-DE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-BE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 - EUCTR2011-003448-28-AT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States
HL161BKN
Immunovant Sciences, GmbH
2023 Phase 2 EUCTR2022-002718-17-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-SE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-RO Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-NO Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-FI Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-DK Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-DE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-BG Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-BE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
Human immunoglobulin G
Aarhus University Hospital
2019 Phase 4 EUCTR2018-003592-34-DK Denmark
Aarhus Unversity Hospital
2017 Phase 4 EUCTR2017-002024-24-DK Denmark
Human normal immunoglobulin
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Aarhus University Hospital
2013 Phase 2 EUCTR2013-001428-20-DK Denmark
Aarhus University Hospital, Department of Neurology
2009 Phase 2 EUCTR2009-013930-25-DK Denmark
BAXALTA INNOVATIONS GMBH
2016 Phase 3 EUCTR2016-000374-37-IT Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
BAXTER S.P.A.
2018 Phase 3 EUCTR2014-005496-87-IT Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Baxalta Innovation GmbH
2016 Phase 3 EUCTR2014-005496-87-DE Argentina;Austria;Belgium;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Baxalta Innovations GmbH
2020 Phase 3 EUCTR2016-000374-37-HR Argentina;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2019 Phase 3 EUCTR2016-000374-37-PL Argentina;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2019 Phase 3 EUCTR2016-000374-37-DE Argentina;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Turkey;United Kingdom;United States
2019 Phase 3 EUCTR2014-005496-87-HR Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2017 Phase 3 EUCTR2016-000374-37-NO Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2016-000374-37-GR Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2016-000374-37-GB Argentina;Brazil;Canada;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2016-000374-37-ES Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2016-000374-37-DK Canada;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2016-000374-37-CZ Argentina;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2014-005496-87-PL Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2017 Phase 3 EUCTR2014-005496-87-AT Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2016-000374-37-FR Canada;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2016 Phase 3 EUCTR2014-005496-87-SK Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2014-005496-87-NO Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2014-005496-87-GR Austria;Belgium;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Netherlands;Norway;Peru;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2014-005496-87-DK Austria;Canada;Czech Republic;Denmark;Germany;Greece;Israel;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 Phase 3 EUCTR2014-005496-87-SE Argentina;Austria;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 - EUCTR2014-005496-87-GB Canada;Czech Republic;Denmark;Germany;Italy;Netherlands;Norway;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 Phase 3 EUCTR2014-005496-87-ES Austria;Canada;Croatia;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 Phase 3 EUCTR2014-005496-87-CZ Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Baxter Innovations GmbH
2009 - EUCTR2009-013841-27-DK Denmark
CSL BEHRING GMBH
2012 Phase 3 EUCTR2011-003448-28-IT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;Germany;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
CSL Behring GmbH
2015 Phase 3 EUCTR2013-004157-24-CZ Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2015 Phase 3 EUCTR2011-003448-28-PL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2015 - EUCTR2011-003448-28-LT Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2011-003448-28-EE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-004157-24-NL Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-IT Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-GB Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-004157-24-FI Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-ES Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-DE Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2012 Phase 3 EUCTR2011-003448-28-NL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-GB Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-FI Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-ES Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-DE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-BE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 - EUCTR2011-003448-28-AT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States
2010 - EUCTR2009-017672-24-FI Finland
2010 Phase 3 EUCTR2009-017672-24-BE Belgium;Finland
LFB BIOTECHNOLOGIES
2016 Phase 3 EUCTR2013-005558-31-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom
2015 Phase 3 EUCTR2013-005558-31-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom
2015 Phase 3 EUCTR2013-005558-31-FR France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
2015 Phase 3 EUCTR2013-005558-31-ES France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
2013 Phase 3 EUCTR2012-001996-34-FR France
Octapharma
- Phase 3 EUCTR2021-003200-40-Outside-EU/EEA United States
Rigshospitalet
2015 Phase 2 EUCTR2015-003453-18-DK Denmark
Teijin Pharma Limited
2014 Phase 3 JPRN-jRCT2080222422 Japan
2014 Phase 3 JPRN-jRCT2080222421 Japan
Human normal immunoglobulin FOR intravenous administration
LFB BIOTECHNOLOGIES
2016 Phase 3 EUCTR2013-005557-73-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom
2015 Phase 3 EUCTR2012-001995-12-IT France;Italy;Spain;United Kingdom
2014 Phase 3 EUCTR2013-005557-73-IT France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
2014 Phase 3 EUCTR2013-005557-73-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom
2014 Phase 3 EUCTR2013-005557-73-FR France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
2014 Phase 3 EUCTR2013-005557-73-ES France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
2013 Phase 3 EUCTR2012-001995-12-GB France;Italy;Spain;United Kingdom
2013 Phase 3 EUCTR2012-001995-12-FR France;Spain;United Kingdom
2013 Phase 3 EUCTR2012-001995-12-ES France;Spain;United Kingdom
Laboratoire français de Fractionnement et de Biotechnologies
2013 Phase 3 NCT01951924 France;Italy;Spain;United Kingdom
Hyaluronidase
Nishizawa Atsushi
2021 Phase 3 JPRN-jRCT2051210110 -
Hyqvia
Baxalta now part of Shire
2016 Phase 3 NCT02955355 Argentina;Brazil;Canada;Colombia;Czechia;Denmark;France;Germany;Greece;Italy;Mexico;Poland;Serbia;Slovakia;Spain;Turkey;United Kingdom;United States
2015 Phase 3 NCT02549170 Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Johannes Jakobsen
2016 Phase 2 NCT02556437 Denmark
Rigshospitalet
2015 Phase 2 EUCTR2015-003453-18-DK Denmark
Takeda
2025 Phase 3 NCT06747351 Argentina;Czechia;Denmark;Germany;Greece;Italy;Japan;Poland;Spain;Sweden;United States
UMC Utrecht
2016 Phase 3 EUCTR2015-000828-28-NL Netherlands
Hyqvia - 100 MG/ML - soluzione PER infusione - USO sottocutaneo - flaconcino (vetro) 300 ML E flaconcino (vetro) 15 ML - 1 flaconcino + 1 flaconcino
BAXTER S.P.A.
2018 Phase 3 EUCTR2014-005496-87-IT Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Hyqvia 100 MG/ML solution FOR infusion FOR subcutaneous USE
BAXALTA INNOVATIONS GMBH
2016 Phase 3 EUCTR2016-000374-37-IT Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
Baxalta Innovation GmbH
2016 Phase 3 EUCTR2014-005496-87-DE Argentina;Austria;Belgium;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Baxalta Innovations GmbH
2020 Phase 3 EUCTR2016-000374-37-HR Argentina;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2019 Phase 3 EUCTR2016-000374-37-PL Argentina;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2019 Phase 3 EUCTR2016-000374-37-DE Argentina;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Turkey;United Kingdom;United States
2019 Phase 3 EUCTR2014-005496-87-HR Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2017 Phase 3 EUCTR2016-000374-37-NO Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2016-000374-37-GR Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2016-000374-37-GB Argentina;Brazil;Canada;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2016-000374-37-ES Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2016-000374-37-DK Canada;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2016-000374-37-CZ Argentina;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2017 Phase 3 EUCTR2014-005496-87-PL Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2017 Phase 3 EUCTR2014-005496-87-AT Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2016-000374-37-FR Canada;Colombia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
2016 Phase 3 EUCTR2014-005496-87-SK Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2014-005496-87-NO Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2014-005496-87-GR Austria;Belgium;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Netherlands;Norway;Peru;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2014-005496-87-DK Austria;Canada;Czech Republic;Denmark;Germany;Greece;Israel;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 Phase 3 EUCTR2014-005496-87-SE Argentina;Austria;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 - EUCTR2014-005496-87-GB Canada;Czech Republic;Denmark;Germany;Italy;Netherlands;Norway;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 Phase 3 EUCTR2014-005496-87-ES Austria;Canada;Croatia;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 Phase 3 EUCTR2014-005496-87-CZ Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
I10
LFB BIOTECHNOLOGIES
2016 Phase 3 EUCTR2013-005558-31-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom
2016 Phase 3 EUCTR2013-005557-73-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom
2015 Phase 3 EUCTR2013-005558-31-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom
I10E
LFB BIOTECHNOLOGIES
2015 Phase 3 EUCTR2013-005558-31-IT France;Germany;Italy;Mexico;Morocco;Spain;Turkey;United Kingdom
2015 Phase 3 EUCTR2013-005558-31-FR France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
2015 Phase 3 EUCTR2013-005558-31-ES France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
2015 Phase 3 EUCTR2012-001995-12-IT France;Italy;Spain;United Kingdom
2014 Phase 3 EUCTR2013-005557-73-IT France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
2014 Phase 3 EUCTR2013-005557-73-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom
2014 Phase 3 EUCTR2013-005557-73-FR France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
2014 Phase 3 EUCTR2013-005557-73-ES France;Germany;Italy;Mexico;Morocco;Spain;Tunisia;Turkey;United Kingdom
2013 Phase 3 EUCTR2012-001995-12-GB France;Italy;Spain;United Kingdom
2013 Phase 3 EUCTR2012-001995-12-FR France;Spain;United Kingdom
2013 Phase 3 EUCTR2012-001995-12-ES France;Spain;United Kingdom
Laboratoire français de Fractionnement et de Biotechnologies
2015 Phase 3 NCT02317562 France;Italy;Spain;Tunisia;Turkey;United Kingdom
2015 Phase 3 NCT02293460 France;Italy;Morocco;Spain;Tunisia;Turkey;United Kingdom
2013 Phase 3 NCT01951924 France;Italy;Spain;United Kingdom
Igiv gammagard liquid/kiovig
Baxalta now part of Shire
2015 Phase 3 NCT02549170 Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Igiv gamunex®-C
Baxalta now part of Shire
2015 Phase 3 NCT02549170 Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Igpro10
CSL BEHRING GMBH
2012 Phase 3 EUCTR2011-003448-28-IT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;Germany;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
CSL Behring
2019 Phase 4 NCT03684018 Canada;United States
2012 Phase 3 NCT01545076 Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
CSL Behring GmbH
2015 Phase 3 EUCTR2011-003448-28-PL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2015 - EUCTR2011-003448-28-LT Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2011-003448-28-EE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-NL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-GB Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-FI Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-ES Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-DE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-BE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 - EUCTR2011-003448-28-AT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States
Igpro20
CSL Behring
2014 Phase 3 NCT02027701 Australia;Canada;Czech Republic;Czechia;Finland;France;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
2012 Phase 3 NCT01545076 Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
CSL Behring GmbH
2015 Phase 3 EUCTR2013-004157-24-CZ Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2015 Phase 3 EUCTR2011-003448-28-PL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2015 - EUCTR2011-003448-28-LT Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2011-003448-28-EE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-004157-24-NL Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-IT Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-GB Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-004157-24-FI Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-ES Australia;Canada;Czech Republic;European Union;Finland;Germany;Israel;Italy;Japan;Netherlands;Spain;United States
2014 Phase 3 EUCTR2013-004157-24-DE Australia;Canada;Czech Republic;European Union;Finland;Germany;Italy;Japan;Netherlands;Spain;United States
2012 Phase 3 EUCTR2011-003448-28-NL Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-GB Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-FI Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-ES Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-DE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-CZ Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 Phase 3 EUCTR2011-003448-28-BE Australia;Austria;Belgium;Canada;Czech Republic;Estonia;European Union;Finland;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States
2012 - EUCTR2011-003448-28-AT Argentina;Australia;Austria;Belgium;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States
Igvena*FL 200ML 10G+SET
KEDRION
2007 - EUCTR2005-001136-76-IT Italy
Imeroprubart
Immunovant Sciences GmbH
2025 Phase 2 NCT07032662 Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Colombia;Denmark;Estonia;Finland;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey (Türkiye);United Kingdom;United States
Immune globulin
Baxalta now part of Shire
2008 Phase 3 NCT00666263 Canada;Denmark;Netherlands;Poland;United States
National Center for Research Resources (NCRR)
1992 Phase 3 NCT00004772 -
Nishizawa Atsushi
2021 Phase 3 JPRN-jRCT2051210110 -
University of South Florida
2014 - NCT02465359 United States
Immune globulin (human) 10% solution FOR intravenous administration
Kedrion S.p.A.
2026 Phase 3 NCT06752356 United States
Immune globulin 10% intravenous solution
Vera Bril
2017 Phase 3 NCT03166527 Canada
Immune globulin IV (human), 10% caprylate/chromatography purified
Grifols Therapeutics Inc.
2004 Phase 3 NCT00220740 Argentina;Canada;Czech Republic;Former Serbia and Montenegro;Germany;Israel;Italy;Mexico;Poland;Serbia;United States
Immunoadsorption
University of Ulm
2023 Phase 2 NCT04881682 Germany
Immunoglobulin
University of Aarhus
2020 Phase 4 NCT04589299 Denmark
Yamamoto Akihiko
2024 Phase 3 JPRN-jRCT2051240028 -
Immunoglobulin G
CSL Behring AG
2008 Phase 2 EUCTR2007-000710-37-GB Germany;Italy;United Kingdom
2007 - EUCTR2007-000710-37-DE Germany;Italy;United Kingdom
CSL Behring GmbH
2010 - EUCTR2009-017672-24-FI Finland
2010 Phase 3 EUCTR2009-017672-24-BE Belgium;Finland
Octapharma Pharmazeutika Produktionsges.m.b.H.
2017 Phase 3 EUCTR2015-005443-14-SE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-PL Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-HU Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-DK Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-DE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-CZ Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-BG Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
Immunoglobulin perfusion
Centre Hospitalier Universitaire de Saint Etienne
2004 Phase 3 NCT01349270 France
Immunoglobulina normale umana
BAXTER S.P.A.
2018 Phase 3 EUCTR2014-005496-87-IT Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Immunoglobulina umana normale
BAXALTA INNOVATIONS GMBH
2016 Phase 3 EUCTR2016-000374-37-IT Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom
Immunoglobulina umana normale PER somministrazione endovenosa
LFB BIOTECHNOLOGIES
2015 Phase 3 EUCTR2013-005558-31-IT France;Germany;Italy;Mexico;Morocco;Spain;Turkey;United Kingdom
Immunoglobuline G
Octapharma AG
2011 Phase 2;Phase 3 EUCTR2009-017805-13-CZ Bulgaria;Czech Republic
2011 - EUCTR2009-017805-13-BG Bulgaria;Czech Republic;India;Mexico;Poland;Romania;Serbia;Ukraine
2010 Phase 2;Phase 3 EUCTR2009-017805-13-RO Bulgaria;Czech Republic;Romania
Immunoglobuline humaine normale
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2007 - EUCTR2006-006392-21-FR France
Immunoglobulins
CSL Behring AG
2007 - EUCTR2007-000710-37-IT Germany;Italy;United Kingdom
KEDRION
2007 - EUCTR2005-001136-76-IT Italy
Rigshospitalet, Denmark
2014 - NCT02111590 Denmark
University of Ulm
2023 Phase 2 NCT04881682 Germany
IMVT-1401
Immunovant Sciences, GmbH
2023 Phase 2 EUCTR2022-002718-17-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-SE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-RO Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-NO Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-FI Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-DK Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-DE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-BG Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-BE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
Interferon BETA-1A
Biogen Idec
2004 Phase 2 NCT00099489 Australia;Canada;United Kingdom;United States
Intratect
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Intravenous gammaglobulin
University of Aarhus
2005 - NCT00305266 Denmark
Intravenous immune globulin G
Rutgers, The State University of New Jersey
2022 Phase 1 NCT05584631 United States
Intravenous immunoglobulin
CIDP Study Group
2006 - JPRN-UMIN000000674 Japan
National Institute of Neurological Disorders and Stroke (NINDS)
1990 Phase 2 NCT00001287 United States
University of Aarhus
2005 Phase 2 NCT00268788 Denmark
University of Minnesota
2015 - NCT02414490 United States
University of Toronto
2015 Phase 4 NCT02372149 Canada
argenx
2024 Phase 3 NCT06742190 Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Latvia;Lithuania;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;Slovenia;Spain;Switzerland;United Kingdom;United States
Iqymune
LFB BIOTECHNOLOGIES
2016 Phase 3 EUCTR2013-005558-31-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom
2016 Phase 3 EUCTR2013-005557-73-DE France;Germany;Italy;Poland;Spain;Tunisia;Turkey;United Kingdom
2015 Phase 3 EUCTR2013-005558-31-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom
2014 Phase 3 EUCTR2013-005557-73-GB France;Germany;Italy;Spain;Tunisia;Turkey;United Kingdom
Ivig
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Assistance Publique - Hôpitaux de Paris
2015 - NCT02404298 France
Kamino Eriko
2025 Phase 3 JPRN-jRCT2051250110 Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Korea;Spain;Sweden;Switzerland;Tunisia;Turkey;USA;United Kingdom
Narita Takanori
2025 Phase 3 JPRN-jRCT2061250020 Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Italy;Japan;Korea;Latvia;Lithuania;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;Slovenia;Spain;Sweden;Switzerland;United Kingdom;United States
National Institute of Neurological Disorders and Stroke (NINDS)
1990 Phase 2 NCT00001287 United States
Obara Kentaro
2024 Phase 3 JPRN-jRCT2031240206 Argentina;Belgium;Brazil;Canada;China;Czechia;Denmark;Germany;Hungary;Israel;Japan;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United States
Sanofi
2024 Phase 3 NCT06290141 Argentina;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Mexico;Norway;Portugal;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey (Türkiye);United Kingdom;United States
University of Toronto
2015 Phase 4 NCT02372149 Canada
argenx
2025 Phase 3 NCT06920004 Argentina;Austria;Czechia;Estonia;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Singapore;Slovakia;Slovenia;South Korea;Spain;Sweden;Switzerland;Turkey (Türkiye);United Kingdom;United States
2024 Phase 3 NCT06742190 Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Latvia;Lithuania;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;Slovenia;Spain;Switzerland;United Kingdom;United States
JNJ-80202135
Tominaga Yushin
2022 Phase 2-3 JPRN-jRCT2041220037 Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Greece;Italy;Japan;Korea Republic Of;Mexico;Poland;Portugal;Spain;Taiwan;United Kingdom Of Great Britain;United States Of America
KINE-101
Kine Sciences Co., Ltd.
2024 Phase 1 NCT07343310 South Korea
Kiovig
Erasmus MC
2014 Phase 4 EUCTR2013-004988-32-NL Netherlands
2014 Phase 4 EUCTR2012-005150-34-NL Netherlands
LFB BIOTECHNOLOGIES
2015 Phase 3 EUCTR2012-001995-12-IT France;Italy;Spain;United Kingdom
2013 Phase 3 EUCTR2012-001995-12-GB France;Italy;Spain;United Kingdom
2013 Phase 3 EUCTR2012-001995-12-FR France;Spain;United Kingdom
2013 Phase 3 EUCTR2012-001995-12-ES France;Spain;United Kingdom
Laboratoire français de Fractionnement et de Biotechnologies
2013 Phase 3 NCT01951924 France;Italy;Spain;United Kingdom
Kiovig - 100 MG/ML soluzione PER infusione USO intravenoso flacone vetro 1 G/10 ML 1 flacone
BAXTER S.P.A.
2018 Phase 3 EUCTR2014-005496-87-IT Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Kiovig 100 MG/ML solution FOR infusion
Baxalta Innovation GmbH
2016 Phase 3 EUCTR2014-005496-87-DE Argentina;Austria;Belgium;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Baxalta Innovations GmbH
2019 Phase 3 EUCTR2014-005496-87-HR Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2017 Phase 3 EUCTR2014-005496-87-PL Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2017 Phase 3 EUCTR2014-005496-87-AT Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2014-005496-87-SK Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2014-005496-87-NO Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2014-005496-87-GR Austria;Belgium;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Netherlands;Norway;Peru;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2016 Phase 3 EUCTR2014-005496-87-DK Austria;Canada;Czech Republic;Denmark;Germany;Greece;Israel;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 Phase 3 EUCTR2014-005496-87-SE Argentina;Austria;Canada;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 - EUCTR2014-005496-87-GB Canada;Czech Republic;Denmark;Germany;Italy;Netherlands;Norway;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 Phase 3 EUCTR2014-005496-87-ES Austria;Canada;Croatia;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
2015 Phase 3 EUCTR2014-005496-87-CZ Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Baxter Innovations GmbH
2009 - EUCTR2009-013841-27-DK Denmark
KITE-363
Kite, A Gilead Company
2026 Phase 1 NCT07304154 Australia;United States
Laboratory biomarker analysis
Fred Hutchinson Cancer Center
2008 Phase 2 NCT00716066 United States
Lipoic acid
Oregon Health and Science University
2009 Phase 2 NCT00962429 United States
Lumbar puncture
University of Aarhus
2015 - NCT02271724 Denmark
Lymphodepleting conditioning
Tongji Hospital
2025 Early Phase 1 NCT07337785 China
M281/JNJ-80202135
Janssen-Cilag International NV
2022 Phase 2;Phase 3 EUCTR2021-003234-37-SK Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
2022 Phase 2;Phase 3 EUCTR2021-003234-37-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
2022 Phase 2;Phase 3 EUCTR2021-003234-37-PL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
2022 Phase 2;Phase 3 EUCTR2021-003234-37-FR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
2022 Phase 2;Phase 3 EUCTR2021-003234-37-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
2022 Phase 2;Phase 3 EUCTR2021-003234-37-CZ Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
Mabthera - 1 fiala 500 MG 50 ML
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 2 EUCTR2018-001347-31-IT Italy
2018 Phase 3 EUCTR2017-005034-36-IT Italy
Maxtrex tablets
Guy's & St Thomas's NHS Foundation Trust
2006 Phase 4 EUCTR2005-003382-16-BE Belgium;Italy;United Kingdom
2005 Phase 4 EUCTR2005-003382-16-GB Belgium;Italy;United Kingdom
ISTITUTO CLINICO HUMANITAS
2006 - EUCTR2005-003382-16-IT Italy;United Kingdom
MD1003
MEDDAY PHARMACEUTICALS
2016 Phase 2 EUCTR2015-001150-15-FR France
MedDay Pharmaceuticals SA
2016 Phase 2 NCT02967679 France
Melphalan
Fred Hutchinson Cancer Center
2008 Phase 2 NCT00716066 United States
Menjugate
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Methotrexate
Guy's & St Thomas's NHS Foundation Trust
2006 Phase 4 EUCTR2005-003382-16-BE Belgium;Italy;United Kingdom
2005 Phase 4 EUCTR2005-003382-16-GB Belgium;Italy;United Kingdom
ISTITUTO CLINICO HUMANITAS
2006 - EUCTR2005-003382-16-IT Italy;United Kingdom
Methylprednisolone
Academic Medical Centre, Amsterdam, NL
2019 Phase 3 EUCTR2017-002511-34-GB Netherlands;United Kingdom
Academisch Medisch Centrum
2018 Phase 3 EUCTR2017-002511-34-NL Netherlands;United Kingdom
Metilprednisolone sodio succinato
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2017-005034-36-IT Italy
N. meningitidis group C polysaccharide
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Newgam
Octapharma
2011 Phase 2/Phase 3 NCT01225276 -
Octapharma AG
2011 Phase 2;Phase 3 EUCTR2009-017805-13-CZ Bulgaria;Czech Republic
2011 - EUCTR2009-017805-13-BG Bulgaria;Czech Republic;India;Mexico;Poland;Romania;Serbia;Ukraine
2010 Phase 2;Phase 3 EUCTR2009-017805-13-RO Bulgaria;Czech Republic;Romania
Octapharma Pharmazeutika Produktionsges.m.b.H.
2017 Phase 3 EUCTR2015-005443-14-SE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-PL Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-HU Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-DK Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-DE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-CZ Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-BG Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
Nipocalimab
Janssen Research & Development, LLC
2022 Phase 2/Phase 3 NCT05327114 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Mexico;Poland;Portugal;Romania;Slovakia;South Africa;South Korea;Spain;Taiwan;United Kingdom;United States
Janssen-Cilag International NV
2022 Phase 2;Phase 3 EUCTR2021-003234-37-SK Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
2022 Phase 2;Phase 3 EUCTR2021-003234-37-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
2022 Phase 2;Phase 3 EUCTR2021-003234-37-PL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Türkiye;United Kingdom;United States
2022 Phase 2;Phase 3 EUCTR2021-003234-37-FR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
2022 Phase 2;Phase 3 EUCTR2021-003234-37-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
2022 Phase 2;Phase 3 EUCTR2021-003234-37-CZ Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States
Tominaga Yushin
2022 Phase 2-3 JPRN-jRCT2041220037 Argentina;Australia;Belgium;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Greece;Italy;Japan;Korea Republic Of;Mexico;Poland;Portugal;Spain;Taiwan;United Kingdom Of Great Britain;United States Of America
NPB-01
Nihon Pharmaceutical Co., Ltd
2013 Phase 3 NCT01827072 Japan
2013 Phase 3 NCT01824251 Japan
NT3 blood draw
Zarife Sahenk
2027 - NCT05011006 United States
NVG-2089
Nuvig Therapeutics, Inc.
2025 Phase 2 NCT07027111 United States
Panzyga
Octapharma
2023 Phase 3 NCT04929236 United States
- Phase 3 EUCTR2021-003200-40-Outside-EU/EEA United States
Octapharma Pharmazeutika Produktionsges.m.b.H.
2017 Phase 3 EUCTR2015-005443-14-SE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-PL Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-HU Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-DK Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-DE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-CZ Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
2017 Phase 3 EUCTR2015-005443-14-BG Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Sweden;Ukraine
Paracetamolo
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2017-005034-36-IT Italy
Peripheral blood stem cell transplantation
Fred Hutchinson Cancer Center
2008 Phase 2 NCT00716066 United States
Prednisolone
AMC Medical research BV
2006 - EUCTR2004-002783-24-GB United Kingdom
Prednisone
Centre Hospitalier Universitaire de Saint Etienne
2004 Phase 3 NCT01349270 France
Fred Hutchinson Cancer Center
2008 Phase 2 NCT00716066 United States
Prevenar 13 sospensione PER iniezione
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Privigen
Aarhus University Hospital
2019 Phase 4 EUCTR2018-003592-34-DK Denmark
2013 Phase 2 EUCTR2013-001428-20-DK Denmark
CSL Behring GmbH
2010 - EUCTR2009-017672-24-FI Finland
2010 Phase 3 EUCTR2009-017672-24-BE Belgium;Finland
Rhuph20
Baxalta now part of Shire
2015 Phase 3 NCT02549170 Argentina;Austria;Brazil;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Israel;Italy;Mexico;Norway;Poland;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Nishizawa Atsushi
2021 Phase 3 JPRN-jRCT2051210110 -
UMC Utrecht
2016 - NCT02885259 Netherlands
Riliprubart
Huashan Hospital, Fudan University
2025 Phase 3 ChiCTR2500108198 China
Obara Kentaro
2025 Phase 3 JPRN-jRCT2031240109 Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Mexico;Netherlands;Poland;Portugal;Republic of Korea;Spain;Sweden;Taiwan;Turkey;United States
2024 Phase 3 JPRN-jRCT2031240206 Argentina;Belgium;Brazil;Canada;China;Czechia;Denmark;Germany;Hungary;Israel;Japan;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United States
Sanofi
2025 Phase 3 NCT06859099 Argentina;Brazil;Canada;Chile;China;Czechia;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Portugal;Serbia;South Korea;Spain;Sweden;Turkey (Türkiye);United States
2024 Phase 3 NCT06290141 Argentina;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Mexico;Norway;Portugal;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey (Türkiye);United Kingdom;United States
2024 Phase 3 NCT06290128 Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Mexico;Netherlands;Poland;Portugal;South Korea;Spain;Sweden;Switzerland;Taiwan;Turkey (Türkiye);United States
Ripertamab
Second Affiliated Hospital of Army Medical University
2026 - ChiCTR2600120227 China
Zhongming Qiu
2025 Phase 3 NCT06858722 -
Rituximab
Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC)
2024 Phase 3 NCT06714838 Netherlands
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 2 EUCTR2018-001347-31-IT Italy
2018 Phase 3 EUCTR2017-005034-36-IT Italy
Iijima Masahiro
2019 Phase 2 JPRN-jRCT2041180037 -
Istituto Clinico Humanitas
2019 Phase 3 NCT06325943 Italy
2019 Phase 2 NCT05877040 Italy
Katsuno Masahisa
2021 Phase 2 JPRN-jRCTs041210046 -
Nagoya University
2019 Phase 2 NCT03864185 Japan
Nagoya University Hospital
2019 Phase 2 JPRN-UMIN000035753 Japan
University of Kansas Medical Center
2025 Phase 2 NCT04480450 -
Rozanolixizumab
UCB Biopharma S.P.R.L.
2019 Phase 2 NCT03861481 Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
UCB Biopharma SPRL
2020 Phase 2 EUCTR2018-004392-12-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2020 Phase 2 EUCTR2018-004392-12-DE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2018-004392-12-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2018-004392-12-FR Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2018-004392-12-ES Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2018-004392-12-DK Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-FR Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-ES Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-DK Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-DE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
UCB Biopharma SRL
2021 - NCT05014724 -
2019 Phase 2 NCT04051944 Belgium;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2018-004392-12-BE Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-BE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
RVG 51680
Department of Neurology, Academic Medical Center
2014 - EUCTR2013-005363-52-NL Netherlands
RVG 56083
Academisch Medisch Centrum
2018 Phase 3 EUCTR2017-002511-34-NL Netherlands;United Kingdom
RVT-1401
Immunovant Sciences, GmbH
2023 Phase 2 EUCTR2022-002718-17-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-SE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-RO Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-NO Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-FI Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-DK Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-DE Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-BG Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
2023 Phase 2 EUCTR2022-002718-17-BE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Denmark;Finland;Germany;Greece;Ireland;Italy;Korea, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States
SAR445088
Bioverativ, a Sanofi company
2021 Phase 2 NCT04658472 Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain;United States
Obara Kentaro
2025 Phase 3 JPRN-jRCT2031240109 Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czechia;Denmark;France;Germany;Greece;Italy;Japan;Mexico;Netherlands;Poland;Portugal;Republic of Korea;Spain;Sweden;Taiwan;Turkey;United States
2024 Phase 3 JPRN-jRCT2031240206 Argentina;Belgium;Brazil;Canada;China;Czechia;Denmark;Germany;Hungary;Israel;Japan;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United States
Sanofi-Aventis Recherche & Développement
2021 Phase 2 EUCTR2020-004006-54-PL Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain
2021 Phase 2 EUCTR2020-004006-54-NL Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain
2021 Phase 2 EUCTR2020-004006-54-DE Canada;China;France;Germany;Italy;Netherlands;Poland;Serbia;Spain
SC investigational needle sets
Takeda
2025 Phase 3 NCT06747351 Argentina;Czechia;Denmark;Germany;Greece;Italy;Japan;Poland;Spain;Sweden;United States
Sodium chloride
Academic Medical Centre, Amsterdam, NL
2019 Phase 3 EUCTR2017-002511-34-GB Netherlands;United Kingdom
Academisch Medisch Centrum
2018 Phase 3 EUCTR2017-002511-34-NL Netherlands;United Kingdom
Department of Neurology, Academic Medical Center
2014 - EUCTR2013-005363-52-NL Netherlands
Soliris
Greater Glasgow and Clyde NHS Board and The University Of Glasgow
2009 - EUCTR2008-005748-18-GB United Kingdom
Solu medrol - 125 MG/2 ML polvere E solvente PER soluzione iniettabile 1 flacone A doppia camera DA 125 MG/2 ML
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2017-005034-36-IT Italy
Subcutaneous immune globulin G
Rutgers, The State University of New Jersey
2022 Phase 1 NCT05584631 United States
Subcutaneous immunoglobulin
University of Aarhus
2010 Phase 2 NCT01017159 Denmark
2005 Phase 2 NCT00268788 Denmark
Subcuvia
Aarhus University Hospital, Department of Neurology
2009 Phase 2 EUCTR2009-013930-25-DK Denmark
Aarhus Unversity Hospital
2017 Phase 4 EUCTR2017-002024-24-DK Denmark
Johannes Jakobsen
2016 Phase 2 NCT02556437 Denmark
Rigshospitalet
2015 Phase 2 EUCTR2015-003453-18-DK Denmark
Syngeneic bone marrow transplantation
Fred Hutchinson Cancer Center
2008 Phase 2 NCT00716066 United States
TAK-411
Takeda
2025 Phase 2 NCT06798012 Canada;Colombia;United States
TAK-771
Nishizawa Atsushi
2021 Phase 3 JPRN-jRCT2051210110 -
Takeda
2022 Phase 3 NCT05084053 Japan
TAK-881
Takeda
2025 Phase 3 NCT06747351 Argentina;Czechia;Denmark;Germany;Greece;Italy;Japan;Poland;Spain;Sweden;United States
Tegeline 50MG/ML
LFB BIOTECHNOLOGIES
2013 Phase 3 EUCTR2012-001996-34-FR France
Telitacicept
Sichuan Academy of Medical Sciences
2025 - NCT07597733 China
Trimeton - 10 MG/1 ML soluzione iniettabile 5 fiale 1 ML
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2017-005034-36-IT Italy
TéGéline
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2007 - EUCTR2006-006392-21-FR France
Ucar T-cell
Tianjin Huanhu Hospital
2025 Early Phase 1 NCT06939166 China
UCB7665
UCB Biopharma SPRL
2020 Phase 2 EUCTR2018-004392-12-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2020 Phase 2 EUCTR2018-004392-12-DE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2018-004392-12-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2018-004392-12-FR Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2018-004392-12-ES Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2018-004392-12-DK Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-FR Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-ES Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-DK Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-DE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
UCB Biopharma SRL
2019 Phase 2 EUCTR2018-004392-12-BE Belgium;Canada;Denmark;France;Germany;Netherlands;Spain;United Kingdom;United States
2019 Phase 2 EUCTR2016-002411-17-BE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
Universal bcma CAR-T
Xuanwu Hospital, Beijing
2025 Early Phase 1 NCT06485232 China
Universal CD19 CAR-?DT cell injection
Tongji Hospital
2026 Phase 1 NCT07526493 China
Universal CD19 CAR-T
Xuanwu Hospital, Beijing
2025 Early Phase 1 NCT06485232 China
Vaccino pneumococcico saccaridico
ARGENX BV
2022 Phase 2 EUCTR2021-003302-50-IT Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Vivaglobin
CSL Behring
2007 Phase 2 NCT00701662 Germany;Italy;Switzerland;United Kingdom
CSL Behring AG
2008 Phase 2 EUCTR2007-000710-37-GB Germany;Italy;United Kingdom
2007 - EUCTR2007-000710-37-IT Germany;Italy;United Kingdom
2007 - EUCTR2007-000710-37-DE Germany;Italy;United Kingdom
Xembify
Grifols Therapeutics LLC
2026 Phase 3 NCT07540221 United States